DaVita (NYSE:DVA) Lowered to “Hold” Rating by Zacks Research

DaVita (NYSE:DVA) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

DVA has been the topic of several other research reports. Deutsche Bank Aktiengesellschaft raised DaVita from a “hold” rating to a “buy” rating and upped their price objective for the company from $126.00 to $220.00 in a research report on Wednesday, May 6th. UBS Group boosted their target price on shares of DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. TD Cowen raised their price target on shares of DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a research note on Monday, May 11th. Truist Financial boosted their price objective on shares of DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a research report on Friday, May 8th. Finally, Barclays upped their target price on shares of DaVita from $158.00 to $194.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 7th. Two analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $199.17.

DaVita Price Performance

Shares of NYSE DVA opened at $234.21 on Monday. The company has a market cap of $15.04 billion, a P/E ratio of 21.73, a PEG ratio of 0.77 and a beta of 0.88. DaVita has a 1 year low of $101.00 and a 1 year high of $239.64. The firm has a 50-day simple moving average of $199.69 and a two-hundred day simple moving average of $158.21.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, beating analysts’ consensus estimates of $2.33 by $0.54. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The firm had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.36 billion. During the same quarter in the prior year, the firm posted $2.00 earnings per share. The company’s quarterly revenue was up 6.0% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities research analysts expect that DaVita will post 15.07 EPS for the current year.

Insider Activity

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the sale, the insider owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. This represents a 12.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Joel Ackerman sold 51,471 shares of DaVita stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $192.10, for a total value of $9,887,579.10. Following the completion of the transaction, the chief financial officer owned 132,434 shares in the company, valued at $25,440,571.40. This represents a 27.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On DaVita

A number of large investors have recently bought and sold shares of DVA. Chapin Davis Inc. acquired a new position in shares of DaVita during the 2nd quarter worth approximately $1,012,000. GAMMA Investing LLC increased its stake in shares of DaVita by 11.2% during the second quarter. GAMMA Investing LLC now owns 3,100 shares of the company’s stock worth $690,000 after purchasing an additional 311 shares in the last quarter. Value Investment Professionals LLC lifted its stake in DaVita by 2.0% in the 2nd quarter. Value Investment Professionals LLC now owns 2,501 shares of the company’s stock worth $556,000 after purchasing an additional 50 shares in the last quarter. CX Institutional grew its holdings in shares of DaVita by 7.7% in the second quarter. CX Institutional now owns 2,480 shares of the company’s stock valued at $552,000 after purchasing an additional 178 shares during the period. Finally, Cozad Asset Management Inc. purchased a new position in DaVita during the first quarter worth about $212,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.